针对膜结合TNF的JAK-STAT激活,抗兄弟杀伤的CAR-T细胞有效地治疗AML和固体瘤
Takahiro Nakashima1,2,3, Tsunenori Ouchida1, Yuichi Ishikawa4
1Division of Tumor Immunology, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan.
Journal for immunotherapy of cancer
|July 14, 2025
概括
化学抗原受体 (CAR) -T细胞疗法针对瘤亡因子N-终端片段 (TNF-NTF) 显示出急性髓性白血病 (AML) 和固体瘤的前景. 具有TNF-NTF向和TNF淘汰的工程CAR-T细胞在体内表现出增强的疗效和持续性.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 化学抗原受体 (CAR) -T细胞治疗对于B细胞恶性瘤是有效的,但由于缺乏特定的标,对于急性髓性白血病 (AML) 和固体瘤是有限的.
- 瘤亡因子 (TNF) 在脱落之前表达在一些AML和固体瘤细胞的表面.
研究的目的:
- 开发和评估针对细胞表面TNF (TNF-NTF) N端片段的CAR-T细胞,用于AML和固体瘤.
- 通过基因工程来提高TNF-NTFCAR-T细胞的疗效和持续性.
主要方法:
- 产生了针对TNF-NTF的单克隆抗体,并开发了针对TNF-NTF的CAR-T细胞.
- 工程化CAR-T细胞具有仿真细胞因子受体 (G6/7R) 和TNF淘汰 (KO) 以改善功能和预防兄弟杀戮.
- 在白血病和卵巢瘤模型中评估了体外细胞毒性和体内抗瘤疗效,扩张和持久性.
主要成果:
- TNF-NTF CAR-T细胞在体外显示了TNF表达性白血病细胞的溶解,但由于扩张不良和兄弟杀伤,体内有效性有限.
- TNF淘汰显著改善了CAR-T细胞活力和增殖,而G6/7R通过JAK-STAT信号增强了效应器功能.
- 表达G6/7R的TNF-KO TNF-NTF CAR-T细胞在体内表现出优异的持久性和耐久的抗白血病和抗瘤疗效,对抗AML和卵巢瘤,没有观察到对正常造血干细胞/原始细胞的细胞毒性.
结论:
- 在AML和固体瘤中,TNF-NTF是CAR-T细胞治疗的可行的细胞表面标.
- 针对TNF-NTF的工程CAR-T细胞,具有TNF淘汰和增强的受体信号,提供了一个有前途的治疗策略.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
811
相关概念视频
The JAK-STAT Signaling Pathway
9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.3K
Tumor Immunotherapy
664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Cytotoxic T Cells-mediated Immune Response
2.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.3K
